Malgorzata Anna Szlek
Pharmacy in Salt Lake City, UT
License number
Utah 5222558-8912
Issued Date
Jan 28, 2003
Expiration Date
Jan 24, 2008
Category
Pharmacy
Type
Limited Controlled Substance-Individual
Address
Address
Salt Lake City, UT
Personal information
See more information about Malgorzata Anna Szlek at radaris.comName
Address
Phone
3660 S Carolyn St, Salt Lake City, UT 84106
3660 Carolyn St, Salt Lake City, UT 84106
Professional information
Ocular Iontophoretic Device And Method For Using The Same
US Patent:
6697668, Feb 24, 2004
Filed:
Jan 25, 2001
Appl. No.:
09/769658
Inventors:
Thomas M. Parkinson - White Salmon WA
Malgorzata Szlek - Salt Lake City UT
Lindsay B. Lloyd - Salt Lake City UT
Malgorzata Szlek - Salt Lake City UT
Lindsay B. Lloyd - Salt Lake City UT
Assignee:
Iomed, Inc. - Salt Lake City UT
International Classification:
A61N 500
US Classification:
604 20, 128770, 606 3, 606 9, 606 10, 607 88
Abstract:
An ocular iontophoretic device for delivering an interferon to an affected area of a living beings eye comprising an active electrode assembly associated with a matrix, wherein the matrix includes an interferon capable of treating viral, immunoregulatory, and/or neovascularization conditions. A method for treating an affected area of a living beings eye comprising the steps of: associating an interferon with an ocular iontophoretic device; positioning at least a portion of the ocular iontophoretic device on the eye of a living being; and iontophoretically delivering the interferon to an affected area of the living beings eye.
Methods For Treating Neoplastic, Angiogenic, Vascular, Fibroblastic, And/Or Immunosuppressive Iregularities Of The Eye And/Or Joint Via Administration Of Combretastatin Based Medicaments, And Iontophoretic Devices For Delivering Combretastatin Based Medicaments
US Patent:
2003009, May 15, 2003
Filed:
Oct 11, 2002
Appl. No.:
10/270273
Inventors:
Thomas Parkinson - White Salmon WA, US
Malgorzata Szlek - Salt Lake City UT, US
Lindsay Lloyd - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
Malgorzata Szlek - Salt Lake City UT, US
Lindsay Lloyd - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
International Classification:
A61K031/075, A61K031/66
US Classification:
514/720000, 514/130000
Abstract:
A method for treating neoplastic, angiogenic, vascular, fibroblastic, immunosuppressive, infectious, metabolic, and/or constitutional irregularities of the eye and/or joint of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular and/or joint area having a neoplastic, angiogenic, fibroblastic, immunosuppressive, infectious, metabolic, and/or constitutional irregularity; providing a combretastatin-A4 based medicament, wherein the combretastatin-A4 based medicament is capable of preventing microtubule assembly, inhibiting the proliferation of endothelial, eukaryotic, and neoplastic cells, or altering their shape and function, as well as providing an anti-inflammatory effect; associating a therapeutically effective concentration of the combretastatin based medicament with the affected ocular and/or joint area of the living subject; and decreasing the neoplastic, angiogenic, vascular, fibroblastic, immunosuppressive, infectious, metabolic and/or constitutional irregularity of the eye and/or joint of the living subject.
Methods For Treating Neoplastic, Angiogenic, Vascular, Fibroblastic, And/Or Immunosuppressive Irregularities Of The Eye And/Or Joint Via Administration Of Combretastatin Based Medicaments, And Iontophoretic Devices For Delivering Combretastatin Based Medicaments
US Patent:
2006014, Jun 29, 2006
Filed:
Feb 21, 2006
Appl. No.:
11/359925
Inventors:
Thomas Parkinson - White Salmon WA, US
Malgorzata Szlek - Salt Lake City UT, US
Lindsay Lloyd - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
Malgorzata Szlek - Salt Lake City UT, US
Lindsay Lloyd - Salt Lake City UT, US
David Vollmer - West Jordan UT, US
International Classification:
A61K 31/66
US Classification:
514130000
Abstract:
A method for treating neoplastic, angiogenic, vascular, fibroblastic, immunosuppressive, infectious, metabolic, and/or constitutional irregularities of the eye and/or joint of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular and/or joint area having a neoplastic, angiogenic, fibroblastic, immunosuppressive, infectious, metabolic, and/or constitutional irregularity; providing a combretastatin-A4 based medicament, wherein the combretastatin-A4 based medicament is capable of preventing microtubule assembly, inhibiting the proliferation of endothelial, eukaryotic, and neoplastic cells, or altering their shape and function, as well as providing an anti-inflammatory effect; associating a therapeutically effective concentration of the combretastatin based medicament with the affected ocular and/or joint area of the living subject; and decreasing the neoplastic, angiogenic, vascular, fibroblastic, immunosuppressive, infectious, metabolic and/or constitutional irregularity of the eye and/or joint of the living subject.
Ocular Iontophoretic Device And Method For Inhibiting Vascular Endothelial Growth Factor (Vegf) Using The Same
US Patent:
2002009, Jul 25, 2002
Filed:
Jan 22, 2001
Appl. No.:
09/767032
Inventors:
Lindsay Lloyd - Salt Lake City UT, US
Thomas Parkinson - White Salmon WA, US
Malgorzata Szlek - Salt Lake City UT, US
Thomas Parkinson - White Salmon WA, US
Malgorzata Szlek - Salt Lake City UT, US
International Classification:
A61M031/00
US Classification:
604/521000
Abstract:
An ocular iontophoretic device for delivering an aptamer to an affected area of a living being's eye for inhibiting VEGF function therein, the device comprising an active electrode assembly associated with a matrix and/or reservoir, wherein the matrix and/or reservoir includes an aptamer capable of inhibiting VEGF function. A method for treating an affected area of a living being's eye, comprising the steps of: associating an aptamer with an ocular iontophoretic device; positioning at least a portion of an ocular iontophoretic device on the eye of the living being; and iontophoretically delivering the aptamer to an affected area of the living being's eye.
Ocular Iontophoretic Device And Method For Inhibiting Vascular Endothelial Growth Factor (Vegf) Using The Same
US Patent:
2002011, Aug 22, 2002
Filed:
Apr 25, 2002
Appl. No.:
10/133288
Inventors:
Lindsay Lloyd - Salt Lake City UT, US
Thomas Parkinson - White Salmon WA, US
Malgorzata Szlek - Salt Lake City UT, US
Thomas Parkinson - White Salmon WA, US
Malgorzata Szlek - Salt Lake City UT, US
International Classification:
A61M035/00
US Classification:
604/020000, 604/290000, 604/521000, 424/427000
Abstract:
An ocular iontophoretic device for delivering an aptamer to an affected area of a living being's eye for inhibiting VEGF function therein, the device comprising an active electrode assembly associated with a matrix and/or reservoir, wherein the matrix and/or reservoir includes an aptamer capable of inhibiting VEGF function. A method for treating an affected area of a living being's eye, comprising the steps of: associating an aptamer with an ocular iontophoretic device; positioning at least a portion of an ocular iontophoretic device on the eye of the living being; and iontophoretically delivering the aptamer to an affected area of the living being's eye.
Improved Buffer Gel For Iontophoresis Electrodes
US Patent:
2005019, Sep 8, 2005
Filed:
Mar 3, 2004
Appl. No.:
10/708432
Inventors:
Thomas Plummer - Salt Lake City UT, US
Malgorzata Szlek - Salt Lake City UT, US
Jon Beck - Salt Lake City UT, US
Malgorzata Szlek - Salt Lake City UT, US
Jon Beck - Salt Lake City UT, US
Assignee:
IOMED, INC. - Salt Lake City UT
International Classification:
A61K031/573, A61N001/30
US Classification:
604020000, 514171000
Abstract:
An iontophoretic delivery device utilizing a polymeric gel matrix to ameliorate pH deviation within the device wherein the pH of the polymeric gel matrix is buffered at select pH ranges in order to reduce skin irritation. The polymeric gel matrix is housed within the iontophoretic delivery device as a buffering agent wherein the matrix provides a suitable physiological pH level above 4.0 and particularly the pH level deviates between approximately 4.1 to approximately 4.9, and preferably at the pH 4.5 for an effective operation of the iontophoretic delivery of a medicament to treat affected areas of a living subject's body.
Ocular Iontophoretic Device And Method For Using The Same
US Patent:
2003002, Jan 30, 2003
Filed:
Jul 20, 2001
Appl. No.:
09/910443
Inventors:
Thomas Parkinson - White Salmon WA, US
Malgorzata Szlek - Salt Lake City UT, US
Lindsay Lloyd - Salt Lake City UT, US
Malgorzata Szlek - Salt Lake City UT, US
Lindsay Lloyd - Salt Lake City UT, US
International Classification:
A61M031/00
US Classification:
604/521000, 604/020000
Abstract:
An ocular iontophoretic device for delivering a composition to an affected area of a living being's eye comprising an active electrode assembly associated with a matrix, wherein the matrix includes a composition capable of treating inflammatory and/or neovascularization conditions. A method for treating an affected area of a living being's eye comprising the steps of: associating a composition with an ocular iontophoretic device; positioning at least a portion of the ocular iontophoretic device on the eye of a living being; and iontophoretically delivering the composition to an affected area of the living being's eye.